1. Home
  2. MLYS vs RHI Comparison

MLYS vs RHI Comparison

Compare MLYS & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.46

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$27.40

Market Cap

2.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
RHI
Founded
2019
1948
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.6B
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
MLYS
RHI
Price
$30.46
$27.40
Analyst Decision
Strong Buy
Hold
Analyst Count
6
6
Target Price
$48.67
$30.33
AVG Volume (30 Days)
1.3M
2.6M
Earning Date
05-11-2026
04-23-2026
Dividend Yield
N/A
8.94%
EPS Growth
37.43
N/A
EPS
N/A
1.33
Revenue
N/A
$5,378,506,000.00
Revenue This Year
N/A
$1.27
Revenue Next Year
N/A
$5.95
P/E Ratio
N/A
$19.84
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$21.83
52 Week High
$47.65
$48.54

Technical Indicators

Market Signals
Indicator
MLYS
RHI
Relative Strength Index (RSI) 65.40 59.56
Support Level $26.85 $26.07
Resistance Level $31.09 $28.35
Average True Range (ATR) 1.92 1.53
MACD 0.64 0.35
Stochastic Oscillator 89.85 77.28

Price Performance

Historical Comparison
MLYS
RHI

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

Share on Social Networks: